Last reviewed · How we verify
STI-6129
At a glance
| Generic name | STI-6129 |
|---|---|
| Also known as | Anti-CD38 antibody drug conjugate, anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) |
| Sponsor | Sorrento Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis (PHASE1)
- An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis (PHASE1)
- Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors (PHASE1)
- Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |